These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9219227)

  • 1. Ribozymes. Their functions and strategies for their use.
    Gibson SA; Shillitoe EJ
    Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and functional aspects of catalytic RNAs.
    Castanotto D; Rossi JJ; Deshler JO
    Crit Rev Eukaryot Gene Expr; 1992; 2(4):331-57. PubMed ID: 1486242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ribozymes for gene therapy.
    Sullivan SM
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-gene therapy: the use of ribozymes to inhibit gene function.
    Couture LA; Stinchcomb DT
    Trends Genet; 1996 Dec; 12(12):510-5. PubMed ID: 9257533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozymes: recent advances in the development of RNA tools.
    Puerta-Fernández E; Romero-López C; Barroso-delJesus A; Berzal-Herranz A
    FEMS Microbiol Rev; 2003 Apr; 27(1):75-97. PubMed ID: 12697343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and optimization of sequence-specific hairpin ribozymes.
    Romero-López C; Barroso-delJesus A; Puerta-Fernández E; Berzal-Herranz A
    Methods Mol Biol; 2004; 252():327-38. PubMed ID: 15017061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient RNA ligation by reverse-joined hairpin ribozymes and engineering of twin ribozymes consisting of conventional and reverse-joined hairpin ribozyme units.
    Ivanov SA; Vauléon S; Müller S
    FEBS J; 2005 Sep; 272(17):4464-74. PubMed ID: 16128815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trans-splicing ribozymes for targeted gene delivery.
    Köhler U; Ayre BG; Goodman HM; Haseloff J
    J Mol Biol; 1999 Feb; 285(5):1935-50. PubMed ID: 9925776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
    Li YL; Torchet C; Vergne J; Maurel MC
    Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
    Denman RB; Smedman M; Kung L
    Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The many faces of the hairpin ribozyme: structural and functional variants of a small catalytic RNA.
    Müller S; Appel B; Krellenberg T; Petkovic S
    IUBMB Life; 2012 Jan; 64(1):36-47. PubMed ID: 22131309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
    Mistry SJ; Benham CJ; Atweh GF
    Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hairpin ribozyme-mediated cleavage of the full-length beta-glucuronidase (GUS) mRNA.
    Hisamatsu S; Sonoki S; Kikuchi Y
    Biosci Biotechnol Biochem; 1995 Feb; 59(2):294-7. PubMed ID: 7766027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.